drugset
drugset / Trial / NCT05683990

Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 Diabetes

NCT05683990 ↗

Phase 2 Active not recruiting 5 enrolled Diamyd Medical AB
RandomizedParallel-groupOpen-labelPrevention

Summary

A 2-arm randomized Phase II Open Label Study to evaluate the safety and feasibility of intralymphatic administration of Diamyd® (Diamyd) also known as retogatein in individuals at risk of Type 1 diabetes carrying the HLA DR3-DQ2 haplotype.

Timeline

Start
2024-07-09
Primary completion
2028-03-31
Completion
2028-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject GAD-Alum Vaccine 4 ug Other

Indications

type 1 diabetes mellitus